From the Department of Epidemiology (R.W., L.B.C., D.B., A.H.), Harvard T.H. Chan School of Public Health, Boston, MA; Department of Epidemiology (R.W., D.B., M.K.I., A.H.), Department of Radiology and Nuclear Medicine (D.B.), and Department of Neurology (M.K.I.), Erasmus Medical Center, Rotterdam, The Netherlands.
Neurology. 2020 Feb 11;94(6):265-272. doi: 10.1212/WNL.0000000000008924. Epub 2020 Jan 16.
To assess the risk of hemorrhagic and ischemic stroke in patients with Alzheimer disease (AD) compared with non-AD controls with similar risk profiles.
A search was conducted on EMBASE and MEDLINE for reports published up to September 26, 2018. Studies were included if they (1) assessed the incidence of stroke in patients diagnosed with AD; (2) included patients with no history of stroke; and (3) reported outcomes by stroke subtype. The main outcome was relative risk of ischemic or hemorrhagic stroke. Furthermore, the rate of stroke occurrence per 1,000 person-years was assessed. A random-effects meta-analysis was undertaken. The risk of bias in included studies was assessed in terms of selection, comparability, and outcome.
A total of 3,605 studies were screened in the title and abstract phase after removing duplicates, and 88 eligible studies were screened for full text. Eight studies met the inclusion criteria representing 121,719 individuals (AD = 73,044; non-AD = 48,675). Five studies were included in the relative risk analysis, among which 4 studies applied formal matching criteria of 44,544 AD and 44,660 non-AD controls. The included studies were based on nationwide registries from Finland, Sweden, Taiwan (2), United Kingdom (2), 1 clinic-based study from the Netherlands, and 1 US population-based cohort. Among patients with AD, the incidence rate of hemorrhagic stroke was 3.41/1000 person-years (95% CI 2.70-4.32) and 2.23 (95% CI 1.72-2.88) among AD cases and non-AD controls, respectively. This is in contrast to 13.98 (95% CI 9.86-19.81) and 12.12 (95% CI 7.55-19.46) for ischemic stroke among AD cases and non-AD controls, respectively. Compared with non-AD controls with similar risk profiles, patients with AD had a relative risk of 1.42 (95% CI 1.23-1.64) for hemorrhagic stroke and 1.15 (95% CI 0.89-1.48) for ischemic stroke.
Compared with non-AD controls with similar risk profiles, patients with AD are likely at a higher risk of hemorrhagic but not ischemic stroke.
评估与具有相似风险特征的非 AD 对照相比,阿尔茨海默病(AD)患者发生出血性和缺血性卒中的风险。
在 EMBASE 和 MEDLINE 上检索截至 2018 年 9 月 26 日发表的报告。如果研究符合以下条件,则纳入:(1)评估诊断为 AD 的患者中风的发生率;(2)纳入无中风病史的患者;(3)报告中风亚型的结果。主要结局为缺血性或出血性中风的相对风险。此外,还评估了每 1000 人年发生卒中的发生率。采用随机效应荟萃分析。根据选择、可比性和结局评估纳入研究的偏倚风险。
在标题和摘要阶段排除重复项后共筛选出 3605 篇研究,对 88 篇符合条件的研究进行了全文筛选。8 项研究符合纳入标准,共纳入 121719 例患者(AD = 73044 例;非 AD = 48675 例)。其中 5 项研究纳入了相对风险分析,其中 4 项研究应用了芬兰、瑞典、中国台湾(2 项)、英国(2 项)、荷兰 1 项基于诊所的研究和美国 1 项基于人群的队列研究的正式匹配标准,共纳入 44544 例 AD 和 44660 例非 AD 对照。纳入的研究基于来自芬兰、瑞典、中国台湾(2 项)、英国(2 项)、荷兰 1 项基于诊所的研究和美国 1 项基于人群的队列研究的全国性登记处,以及 1 项来自荷兰的基于诊所的研究和 1 项来自美国的基于人群的队列研究。AD 患者中出血性卒中的发生率为 3.41/1000 人年(95%CI 2.70-4.32),AD 病例和非 AD 对照分别为 2.23/1000 人年(95%CI 1.72-2.88)。相比之下,AD 病例和非 AD 对照的缺血性卒中发生率分别为 13.98/1000 人年(95%CI 9.86-19.81)和 12.12/1000 人年(95%CI 7.55-19.46)。与具有相似风险特征的非 AD 对照相比,AD 患者发生出血性卒中的相对风险为 1.42(95%CI 1.23-1.64),发生缺血性卒中的相对风险为 1.15(95%CI 0.89-1.48)。
与具有相似风险特征的非 AD 对照相比,AD 患者发生出血性卒中的风险较高,但发生缺血性卒中的风险并无差异。